Text this: Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using ¹⁷⁷Lu-iPSMA and ¹⁷⁷Lu-DOTATOC: Experience after 905 Treatment Doses